Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 3/20 | 0.41 |
| ▸ | RXRB | P28702 | 3/20 | 0.41 |
| ▸ | RXRG | P48443 | 3/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tramazoline SCHEMBL121944 | 0.88 | LMNA (0.69) | LMNACYP2D6CYP2C19ADRA2AADRA2B | |
| Tramazoline SCHEMBL29362958 | 0.87 | LMNA (0.68) | LMNACYP2D6CYP2C19ADRA2AADRA2B | |
| Tramazoline SCHEMBL121943 | 0.87 | LMNA (0.68) | LMNACYP2D6CYP2C19ADRA2AADRA2B | |
| Tramazoline SCHEMBL8378445 | 0.85 | LMNA (0.67) | LMNACYP2D6CYP2C19ADRA2AADRA2B | |
| Indanazoline SCHEMBL151815 | 0.85 | LMNA (0.66) | LMNACYP2D6CYP2C19ADRA2AADRA2B | |
| Indanazoline SCHEMBL3500123 | 0.84 | LMNA (0.65) | LMNACYP2D6CYP2C19ADRA2AADRA2B | |
| Indanazoline SCHEMBL1650054 | 0.84 | LMNA (0.65) | LMNACYP2D6CYP2C19ADRA2AADRA2B | |
| Indanazoline SCHEMBL11372740 | 0.81 | LMNA (0.66) | LMNACYP2D6CYP2C19ADRA2AADRA2B | |
| Indanazoline SCHEMBL3064466 | 0.71 | ADRA1A (0.67) | LMNACYP2D6CYP2C19ADRA2AADRA2B | |
| Trifluoroacetic Acid SCHEMBL17894532 | 0.71 | ALDH1A1 (0.51) | LMNAL3MBTL1KDM4ERXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981498-A2 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. Hoffmann-la Roche AG (CH) | 2008-10-22 | — | — | EP | claimed |
| US-20070197569-A1 | Method for treating central nervous system disorders with substituted 2-imidazoline derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | claimed |
| WO-2007090720-A2 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197569-A1 | Method for treating central nervous system disorders with substituted 2-imidazoline derivatives | CRY1, HTR2C, PER2 | LMNA 1844/4885CYP2D6 436/4885CYP2C19 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.